Jane E Dematte D'Amico

  • 597 Citations
1996 …2022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Undergraduate studies: University of Rochester, BS 1981 Postgraduate studies: SUNY StonyBrook School of Medicine, MD 1986 Internship and Residency, SUNY StonyBrook: Internal Medicine 1986-1989 Chief Resident, SUNY StonyBrook: 1989-1990 Fellowship, Pulmonary and Critical Care Medicine, SUNY StonyBrook: 1990-1993 Northwestern University Kellogg School of Business, MBA: 2006-2008 Board Certification: Internal Medicine, Pulmonary Medicine, Critical Care Medicine

My academic focus parallels my clinical focus. My clinically research has explored the risk of lung cancer in patients with scleroderma and the role of esophageal enlargement in progression of lung disease in Scleroderma. More recently, my research interests have expanded in working with our basic scientists to explore the pathobiology of inflammation, injury and fibrosis in the lungs of patients with ILD and pulmonary fibrosis.

My clinic area of interest and expertise is in the evaluation and management of interstitial lung disease with a particular focus on lung disease associated with connective tissue diseases such as scleroderma, myositis and other connective tissue diseases. I am the director of the Interstitial Lung Disease Program at Northwestern University and run our multidisciplinary ILD bimonthly conference.

Certifications and Licenses

Critical Care Medicine
Pulmonary Disease
Internal Medicine

Training Experience

1990Residency, University Hospital - SUNY
1993Fellowship, University Hospital - SUNY

Education/Academic qualification

MD, SUNY - Stony Brook

… → 1990

Research interests

  • Connective Tissue Associated Interstitial Lung Disease
  • Idiopathic Interstitial Lung Disease

Fingerprint Dive into the research topics where Jane E Dematte D'Amico is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Heat Stroke Medicine & Life Sciences
Infrared Rays Medicine & Life Sciences
Interstitial Lung Diseases Medicine & Life Sciences
Lung Medicine & Life Sciences
Systemic Scleroderma Medicine & Life Sciences
Pulmonary Edema Medicine & Life Sciences
Chronic Obstructive Pulmonary Disease Medicine & Life Sciences
Lung Diseases Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2002 2022

Research Output 1996 2018

Graft vs Host Disease
Lung
Safety
Multiple Myeloma
Bortezomib
4 Citations (Scopus)

Lung transplantation in scleroderma: Recent advances and lessons

Jablonski, R., Dematte D'Amico, J. E. & Bhorade, S., Nov 1 2018, In : Current opinion in rheumatology. 30, 6, p. 562-569 8 p.

Research output: Contribution to journalReview article

Lung Transplantation
Transplants
Pulmonary Hypertension
Lung
Lung Diseases
3 Citations (Scopus)

Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis

Showalter, K., Hoffmann, A., Rouleau, G., Aaby, D., Lee, J., Richardson, C., Dematte D'Amico, J. E., Agrawal, R., Chang, R. W. & Hinchcliff, M., Nov 1 2018, In : Journal of Rheumatology. 45, 11, p. 1572-1576 5 p.

Research output: Contribution to journalArticle

Systemic Scleroderma
Interstitial Lung Diseases
Vital Capacity
Lung
Autoantibodies
20 Citations (Scopus)

Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study

Richardson, C., Agrawal, R., Lee, J., Almagor, O., Nelson, R., Varga, J., Cuttica, M. J., Dematte D'Amico, J. E., Chang, R. W. & Hinchcliff, M. E., Aug 1 2016, In : Seminars in Arthritis and Rheumatism. 46, 1, p. 109-114 6 p.

Research output: Contribution to journalArticle

Systemic Scleroderma
Interstitial Lung Diseases
Dilatation
Cross-Sectional Studies
Tomography
178 Citations (Scopus)

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Tashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J., Arriola, E., Volkmann, E. R., Kafaja, S., Silver, R., Steen, V., Strange, C., Wise, R., Wigley, F., Mayes, M., Riley, D. J., Hussain, S., Assassi, S., Hsu, V. M. & 24 others, Patel, B., Phillips, K., Martinez, F., Golden, J., Connolly, M. K., Varga, J., Dematte D'Amico, J. E., Hinchcliff, M. E., Fischer, A., Swigris, J., Meehan, R., Theodore, A., Simms, R., Volkov, S., Schraufnagel, D. E., Scholand, M. B., Frech, T., Molitor, J. A., Highland, K., Read, C. A., Fritzler, M. J., Kim, G. H. J., Tseng, C. H. & Elashoff, R. M., Sep 1 2016, In : The Lancet Respiratory Medicine. 4, 9, p. 708-719 12 p.

Research output: Contribution to journalArticle

Mycophenolic Acid
Interstitial Lung Diseases
Cyclophosphamide
Joints
Placebos